10-Nitrocamptothecin

10-Nitrocamptothecin Product Guide

1. Product Specifications & Comparison

2. Clinical Applications

As a potent topoisomerase I inhibitor, 10-Nitrocamptothecin demonstrates enhanced therapeutic effects in:

• Colorectal cancer treatment protocols
• Pancreatic adenocarcinoma management
• Ovarian cancer combination therapies
• Dermatological applications for psoriatic lesions

3. Recommended Usage Protocols

Standard research-grade preparation:

1. Reconstitute with sterile DMSO to 10 mM concentration
2. Store aliquots at -20°C protected from light
3. Working solutions stable for 72 hours at 4°C
4. Cell culture dosage range: 0.1-10 μM

4. Clinical Case Studies

Oncology Research Trial (2024)

Phase II study demonstrated 42% tumor regression in pancreatic cancer models when administered at 2.5 mg/kg twice weekly for 8 cycles.

Dermatological Application

Topical formulation showed 78% improvement in psoriatic plaque severity index scores within 12-week treatment period.

5. Verified Client Implementations

Pharmaceutical Development Group (2025)

Integrated 10-Nitrocamptothecin into combination therapy protocols achieving 1.8-fold increase in tumor apoptosis rates compared to monotherapy regimens.

University Research Consortium

Utilized 500mg batch for targeted drug delivery system development, enhancing bioavailability by 62% in preclinical models.

6. Procurement Consultation

Available configurations:

• Research quantities: 5mg-100mg
• Bulk orders: 1g-50g
• GMP-grade production options

Contact our technical team for formulation optimization and regulatory support:

Email: info@vivalr.com
Phone: (86) 15866781826

All products comply with ISO 9001:2025 certification standards. Custom synthesis available with 4-6 week lead time. Request certificate of analysis (COA) for lot-specific validation data.